当前位置: X-MOL 学术Child Adolesc. Psychiatry Ment. Health › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Virtual reality exposure therapy for adolescents with fear of public speaking: a non-randomized feasibility and pilot study.
Child and Adolescent Psychiatry and Mental Health ( IF 5.6 ) Pub Date : 2019-12-27 , DOI: 10.1186/s13034-019-0307-y
Smiti Kahlon 1 , Philip Lindner 1, 2, 3 , Tine Nordgreen 1, 4
Affiliation  

Background Public Speaking Anxiety (PSA) is a common anxiety with onset in adolescence and early adulthood. With the advent of consumer virtual reality (VR) technology, VR-delivered exposure therapy is now a scalable and practical treatment option and has previously been shown to be efficacious with adults. In this non-randomized feasibility and pilot trial, we explore the effect of one-session (90 min) VR-delivered exposure therapy for adolescents (aged 13-16) with PSA. Methods A total of 27 adolescents were recruited from Norwegian high schools and completed self-report measures of PSA twice prior to treatment, 1 week after treatment, and at 1 and 3 month follow-up. Heart rate was recorded during the treatment session. A low-cost head-mounted VR display with a custom-built VR stimuli material depicting a cultural and age appropriate classroom and audience were used when a series of speech (exposure exercises) were performed. Results Linear mixed effects model revealed a significant decrease in PSA symptoms (Cohen's d = 1.53) pre-post treatment, and improvements were maintained at follow-ups. Physiological data revealed a small increase in heart rate during exposure tasks. Based on feedback from the adolescents, the feasibility of the intervention was increased during the trial. Conclusions The results show that low-cost, consumer VR hardware can be used to deliver efficacious treatment for PSA in adolescents, in a feasible one-session format.

中文翻译:

害怕公开演讲的青少年的虚拟现实暴露疗法:非随机可行性和试点研究。

背景公开演讲焦虑(PSA)是一种常见的焦虑,发病于青春期和成年早期。随着消费者虚拟现实 (VR) 技术的出现,VR 提供的暴露疗法现在是一种可扩展且实用的治疗选择,并且之前已被证明对成人有效。在这项非随机可行性和试点试验中,我们探讨了单次(90 分钟)VR 提供的暴露疗法对患有 PSA 的青少年(13-16 岁)的影响。方法 从挪威高中招募 27 名青少年,在治疗前两次、治疗后 1 周以及随访 1 个月和 3 个月时完成 PSA 的自我报告测量。在治疗期间记​​录心率。在进行一系列演讲(暴露练习)时,使用了一种低成本的头戴式 VR 显示器,该显示器带有定制的 VR 刺激材料,描绘了适合文化和年龄的教室和观众。结果 线性混合效应模型显示 PSA 症状 (Cohen's d = 1.53) 治疗前显着减少,并且在随访中保持改善。生理数据显示在暴露任务期间心率略有增加。根据青少年的反馈,在试验期间增加了干预的可行性。结论 结果表明,低成本的消费级 VR 硬件可用于以可行的单次治疗形式为青少年 PSA 提供有效的治疗。结果 线性混合效应模型显示 PSA 症状 (Cohen's d = 1.53) 治疗前显着减少,并且在随访中保持改善。生理数据显示在暴露任务期间心率略有增加。根据青少年的反馈,在试验期间增加了干预的可行性。结论 结果表明,低成本的消费级 VR 硬件可用于以可行的单次治疗形式为青少年 PSA 提供有效的治疗。结果 线性混合效应模型显示 PSA 症状 (Cohen's d = 1.53) 治疗前显着减少,并且在随访中保持改善。生理数据显示在暴露任务期间心率略有增加。根据青少年的反馈,在试验期间增加了干预的可行性。结论 结果表明,低成本的消费级 VR 硬件可用于以可行的单次治疗形式为青少年 PSA 提供有效的治疗。在试验期间增加了干预的可行性。结论 结果表明,低成本的消费级 VR 硬件可用于以可行的单次治疗形式为青少年 PSA 提供有效的治疗。在试验期间增加了干预的可行性。结论 结果表明,低成本的消费级 VR 硬件可用于以可行的单次治疗形式为青少年 PSA 提供有效的治疗。
更新日期:2020-04-22
down
wechat
bug